Art. -Nr.: HY-B0419

Manidipine

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Manidipine is an orally active calcium channel antagonist. Manidipine regulates the expression of cytokines (IL-1β, IL-6). Manidipine has a hypotensive effect. Manidipine can be used in the study of cardiovascular diseases (such as hypertension, myocardial ischemia-reperfusion injury, ventricular hypertrophy), kidney diseases (such as glomerular diseases), and epilepsy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.92%
CAS. Nr.: 89226-50-6
Formel: C₃₅H₃₈N₄O₆
Molecular Weight:610.70

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Manidipine Chemical Structure

CAS. Nr.: 89226-50-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Calcium Channel Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
LLC-PK1	IC₅₀	4.6 μM Compound: Manidipine	TP_TRANSPORTER: inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 uM) in MDR1-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 uM) in MDR1-expressing LLC-PK1 cells	[PMID: 11145223]
LLC-PK1	IC₅₀	4.65 μM Compound: Manidipine	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 uM) in MDR1-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 uM) in MDR1-expressing LLC-PK1 cells	[PMID: 12128170]

In Vitro

Manidipine (1 nM-1 μM; 1-4 h) inhibits the transcription of mRNA for IL-1β and GM-CSF, while enhancing the transcription of IL-6 gene in human mesangial cells stimulated by PDGF-BB^[1].
Manidipine (0.1 nM-1 μM; 20-60 min) inhibits the ET-1-induced [Ca²⁺]i increase in A7r5 cells and glomerular mesangial cells^[2].
Manidipine (1-5 μM; 18 h) completely inhibits IL-6 production induced by acLDL, oxLDL or TNF-α in human endothelial cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Manidipine (1-10 mg/kg; p.o.; once a day; 7 days) reduces systolic blood pressure, increases plasma nitrite/nitrates, and shows a dose-dependent cardioprotective effect against ischemia-reperfusion injury in normocholesterolemic rats^[6].
Manidipine (3 mg/kg; i.g.; once a day; 7 days) hydrochloride prevents Isoproterenol (HY-B0468)-induced left ventricular hypertrophy and the increase in ANP, collagen types I and III, and fibronectin mRNAs in rats^[4].
Manidipine (0.05% in rat chow; p.o.; 2 months or 20 μg/kg; i.v.) hydrochloride shows antihypertensive effect in spontaneously hypertensive rats^[5].
Manidipine (10-30 mg/kg; i.p.; before administration of agents that induced seizures) increases the latency to convulsions and the time of death in PTZ-induced seizure mice^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Spontaneously Hypertensive Rats (SHR) (age 8 weeks); Chronic hypertension renal microcirculation model and acute hypertension renal microcirculation model^[5]
Dosage:

0.05% in rat chow (chronic), 20 μg/kg (acute)
Administration:

Oral administration (chronic, 2 months); Intravenous injection (acute, once)
Result:

Reduced systemic blood pressure, increased renal blood flow by dilating the afferent arterioles, and improved glomerular hypertension by dilating the efferent arterioles in the chronic model.
Decreased systemic blood pressure in the acute model.
Had different effects on renal microcirculation parameters, such as no significant change in SNGFR, SNGPF, or ΔP in some cases.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 89226-50-6
Appearance Solid
Molecular Weight 610.70
Formel C₃₅H₃₈N₄O₆
Color Light yellow to yellow
SMILES

O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCN3CCN(C(C4=CC=CC=C4)C5=CC=CC=C5)CC3
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (3)

All

Sort by:

Journal Impact Factor

Int Immunopharmacol

Regulation of P-glycoprotein through CaMKII/cPLA2 pathway in lymphocytes for treating refractory rheumatoid arthritis by manidipine. [Abstract]

2025 May 27:156:114735. PMID: 40294472
Biomed Pharmacother

Docking and database screening identify manidipine as a potential modulator of matrix metalloproteinase-7 in chronic kidney disease. [Abstract]

2025 Dec:193:118748. PMID: 41232355
bioRxiv

Drug-induced phospholipidosis as an artifact in antiviral drug repurposing. [Abstract]

2025 Nov 21:2025.11.20.689520. PMID: 41332603

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (163.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6375 mL

8.1873 mL

16.3747 mL

5 mM

0.3275 mL

1.6375 mL

3.2749 mL

10 mM

0.1637 mL

0.8187 mL

1.6375 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Roth M, et al. Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci U S A. 1992 May 1;89(9):4071-5. [Content Brief]

[2]. Huang S, et al. Manidipine inhibits endothelin-1-induced [Ca2+]i signaling but potentiates endothelin's effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cells. Am Heart J. 1993 Feb;125(2 Pt 2):589-97. [Content Brief]

[3]. Costa S, et al. Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages. Pharmacol Res. 2010 Sep;62(3):265-70. [Content Brief]

[4]. Yoshiyama M, et al. Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricular hypertrophy. Jpn Circ J. 1998 Jan;62(1):47-52. [Content Brief]

[5]. Tojo A, et al. Effects of manidipine hydrochloride on the renal microcirculation in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1992 Dec;20(6):895-9. [Content Brief]

[6]. Rossoni G, et al. Combined simvastatin-manidipine protect against ischemia-reperfusion injury in isolated hearts from normocholesterolemic rats. Eur J Pharmacol. 2008 Jun 10;587(1-3):224-30. [Content Brief]

[7]. Haraguchi K, et al. Catalepsy induced by manidipine, a calcium channel blocker, in mice. J Pharm Pharmacol. 1996 Apr;48(4):429-32. [Content Brief]

[8]. Souza C N S, et al. 074—(SOA0068) Anticonvulsant activity of acute treatment with manidipine in pentylenetetrazole-and pilocarpine-induced seizure models in mice. Epilepsy & Behavior, 2014, 38: 214.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6375 mL	8.1873 mL	16.3747 mL	40.9366 mL
	5 mM	0.3275 mL	1.6375 mL	3.2749 mL	8.1873 mL
	10 mM	0.1637 mL	0.8187 mL	1.6375 mL	4.0937 mL
	15 mM	0.1092 mL	0.5458 mL	1.0916 mL	2.7291 mL
	20 mM	0.0819 mL	0.4094 mL	0.8187 mL	2.0468 mL
	25 mM	0.0655 mL	0.3275 mL	0.6550 mL	1.6375 mL
	30 mM	0.0546 mL	0.2729 mL	0.5458 mL	1.3646 mL
	40 mM	0.0409 mL	0.2047 mL	0.4094 mL	1.0234 mL
	50 mM	0.0327 mL	0.1637 mL	0.3275 mL	0.8187 mL
	60 mM	0.0273 mL	0.1365 mL	0.2729 mL	0.6823 mL
	80 mM	0.0205 mL	0.1023 mL	0.2047 mL	0.5117 mL
	100 mM	0.0164 mL	0.0819 mL	0.1637 mL	0.4094 mL

Keywords

Manidipine

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Manidipine

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Calcium Channel Blocker Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Autoimmune Disease Compound Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Manidipine

Alle Calcium Channel Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Manidipine Related Classifications

HY-B0419 Related Classifications